Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients.

被引：2
|
作者：
Kapoor, Vidit
Rixe, Olivier
机构：
[1] Univ New Mexico Hosp, Albuquerque, NM USA
[2] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14139
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
    Alvarez, Maite
    Otano, Itziar
    Minute, Luna
    Ochoa, Maria Carmen
    Perez-Ruiz, Elisabeth
    Melero, Ignacio
    Berraondo, Pedro
    CELL STRESS, 2019, 3 (07) : 236 - 239
  • [2] Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    Elisabeth Perez-Ruiz
    Luna Minute
    Itziar Otano
    Maite Alvarez
    Maria Carmen Ochoa
    Virginia Belsue
    Carlos de Andrea
    Maria Esperanza Rodriguez-Ruiz
    Jose Luis Perez-Gracia
    Ivan Marquez-Rodas
    Casilda Llacer
    Martina Alvarez
    Vanesa de Luque
    Carmen Molina
    Alvaro Teijeira
    Pedro Berraondo
    Ignacio Melero
    Nature, 2019, 569 : 428 - 432
  • [3] Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    Perez-Ruiz, Elisabeth
    Minute, Luna
    Otano, Itziar
    Alvarez, Maite
    Carmen Ochoa, Maria
    Belsue, Virginia
    de Andrea, Carlos
    Esperanza Rodriguez-Ruiz, Maria
    Luis Perez-Gracia, Jose
    Marquez-Rodas, Ivan
    Llacer, Casilda
    Alvarez, Martina
    de Luque, Vanesa
    Molina, Carmen
    Teijeira, Alvaro
    Berraondo, Pedro
    Melero, Ignacio
    NATURE, 2019, 569 (7756) : 428 - +
  • [4] Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
    Assal, Amer
    Kaner, Justin
    Pendurti, Gopichand
    Zang, Xingxing
    IMMUNOTHERAPY, 2015, 7 (11) : 1169 - 1186
  • [5] At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Intlekofer, Andrew M.
    Thompson, Craig B.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (01) : 25 - 39
  • [6] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon, Tawee
    Gray, Jhanelle E.
    Antonia, Scott J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312
  • [7] Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    Ju, Mingyi
    Zhang, Jiaojiao
    Deng, Zhuoyuan
    Wei, Minjie
    Ma, Lianghua
    Chen, Ting
    Zhao, Lin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 19
  • [8] Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva, Pushpamali
    Aiello, Marco
    Gu-Trantien, Chunyan
    Migliori, Edoardo
    Willard-Gallo, Karen
    Solinas, Cinzia
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) : 31 - 41
  • [9] Inhibiting CTLA-4 and PD-1 Boosts Response
    不详
    CANCER DISCOVERY, 2013, 3 (07) : 710 - 711
  • [10] Uveal consequences of CTLA-4 and PD-1 inhibition
    Jager, Martine J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
12345